Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD

Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues. Multiple studies have shown that human umbilical cord mesenchymal stem cell has good safety and effectiveness in improving acute or chronic liver injury. Stem cell therapy for end-stage liver disease (ESLD) can be administered through various routes, among which hepatic artery and peripheral vein infusions are the most commonly used in clinical practice. The efficacy of hepatic artery infusion appears to be greater than that of peripheral vein infusion.

NCT Number	NCT06984497
Lead Sponsor	General Hospital of Shenyang Military Region
Conditions	End-Stage Liver Diseases
Enrollment	32 participants
Start Date	2025-09
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-24